The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-09), Prostalund AB's 9-Day RSI is 44.36.
The industry rank for Prostalund AB's 9-Day RSI or its related term are showing as below:
FRA:7PL0's 9-Day RSI is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 48.99
vs FRA:7PL0: 44.36
Prostalund AB (FRA:7PL0) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Prostalund AB 9-Day RSI Related Terms
FRA:7PL0 vs HCA, THC, UHS: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, Prostalund AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostalund AB 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Prostalund AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Prostalund AB's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostalund AB (FRA:7PL0) has a 9-Day RSI of 44.36 as of Jul. 09, 2026.
Is Prostalund AB's 9-Day RSI too high?
Prostalund AB's current 9-Day RSI is 44.36. The Healthcare Providers & Services industry median 9-Day RSI is 48.99. Prostalund AB's value of 44.36 is 9.5% below this industry median. Overall, Prostalund AB has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Prostalund AB's 9-Day RSI compare to HCA and THC?
Prostalund AB's 9-Day RSI of 44.36 can be compared against companies in the Healthcare Providers & Services industry. The industry median 9-Day RSI is 48.99. Prostalund AB's value of 44.36 is 9.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 48.99, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostalund AB's current 9-Day RSI of 44.36 is 9.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 48.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostalund AB's current 9-Day RSI is 44.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostalund AB stock overvalued right now?
Prostalund AB (FRA:7PL0) has a current 9-Day RSI of 44.36. The stock's GF Value™ is €0.02, compared to a current price of €0.00 — trading 97.5% below its estimated fair value. The current 9-Day RSI is 44.36 and 9.5% below the Healthcare Providers & Services industry median of 48.99. Prostalund AB's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Prostalund AB (FRA:7PL0), the current 9-Day RSI is 44.36 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostalund AB (FRA:7PL0) Overvalued in 2026?
Based on GuruFocus' analysis, Prostalund AB stock appears to be undervalued.
The current stock price of €0.00 is trading 97.5% below its estimated GF Value™ of €0.02.
Key valuation signals for FRA:7PL0:
9-Day RSI: 44.36
GF Value™: €0.02 vs. price of €0.00 (97.5% below fair value)
Industry Position: 9.5% below the Healthcare Providers & Services median
No single metric tells the full story. See the FRA:7PL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
10GF Score
Get the complete analysis for FRA:7PL0
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PL0 has been successfully added to your 